VRC HIV MAB-research, development, and production to support HIV monoclonal antibody development - the primary objective is to support cell line development, process development, analytical…
Active Awarded Last action
- Contract number
- 75N91022F00001
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $19,130,043
Award facts
- Opportunity
-
- NIAIDVCRB220024 Solicitation number
- Contract value 99% obligated
-
- $19,130,043.00 Current, with exercised options
- $19,358,814.00 Potential, with all options
- Completion date 84% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Exercise an Option | $8,145,256 | |
| Exercise an Option | $6,330,049 | |
| Original award | $4,654,738 |
About this award
Leidos Biomedical Research Inc. was awarded a $19,358,814 delivery order contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to support human immunodeficiency virus (HIV) monoclonal antibody development. Specifically, the prime contractor will support cell line development, process development, analytical development, reagent production, manufacturing, and testing under the objectives of the prime award. The period of performance for these research and production support services extends through September 15, 2027. The contract vehicle is an unrestricted delivery order issued against an indefinite delivery contract held by Leidos Biomedical Research as a Federally Funded Research and Development Center for the National Cancer Institute, with a potential value of $6.6 billion over five years. Work will be conducted at the prime contractor's place of performance in Fort Detrick, Maryland.
Description
VRC HIV MAB-research, development, and production to support HIV monoclonal antibody development - the primary objective is to support cell line development, process development, analytical development, reagent production, manufacturing, and testing
Quick answers
Who was awarded contract 75N91022F00001?
75N91022F00001 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on February 1, 2022.
How much is contract 75N91022F00001 worth?
The government has obligated $19,130,043 on 75N91022F00001. Its potential value, with all options, is $19,358,814.
Which agency awarded contract 75N91022F00001?
National Cancer Institute (National Institutes of Health) awarded 75N91022F00001, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91022F00001 an order under another contract?
Yes. 75N91022F00001 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91022F00001 competed?
The extent of competition for 75N91022F00001 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award